Omeros Corporation
$ 11.84
4.04%
14 Apr - close price
- Market Cap 852,435,000 USD
- Current Price $ 11.84
- High / Low $ 11.84 / 11.46
- Stock P/E N/A
- Book Value -1.69
- EPS -0.08
- Next Earning Report 2026-05-21
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -5.76 %
- 52 Week High 17.65
- 52 Week Low 2.95
About
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
Analyst Target Price
$38.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-13 | 2025-08-14 | 2025-05-13 | 2025-03-31 | 2024-11-07 | 2024-08-07 | 2024-05-15 | 2024-03-26 | 2023-11-09 | 2023-08-09 | 2023-05-09 |
| Reported EPS | -0.5464 | -0.34 | -0.43 | -0.5408 | -0.55 | -0.64 | -0.97 | -0.63 | -0.15 | -0.6 | -0.59 | -0.54 |
| Estimated EPS | -0.5202 | -0.45 | -0.46 | -0.58 | -0.71 | -0.7 | -1.14 | -0.58 | -0.55 | -0.62 | -0.57 | -0.56 |
| Surprise | -0.0262 | 0.11 | 0.03 | 0.0392 | 0.16 | 0.06 | 0.17 | -0.05 | 0.4 | 0.02 | -0.02 | 0.02 |
| Surprise Percentage | -5.0365% | 24.4444% | 6.5217% | 6.7586% | 22.5352% | 8.5714% | 14.9123% | -8.6207% | 72.7273% | 3.2258% | -3.5088% | 3.5714% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-21 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.4 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OMER
2026-04-12 07:11:17
Omeros Corporation (NASDAQ:OMER) has received a "Moderate Buy" consensus rating from six brokerages, with an average 12-month price target of $40.33, significantly higher than its current share price of $11.49. The company recently reported a surprisingly strong quarterly EPS of $3.14, beating estimates, despite analysts forecasting a negative full-year EPS. Insider David J. Borges sold 30,000 shares, while institutional investors like Vanguard and UBS materially increased their holdings.
2026-04-11 06:39:39
This article provides news and financial updates for OMEROS CORP (NASDAQ: OMER). It highlights the company's current stock price, recent performance, and a report from 12 days prior detailing its Q4 2025 earnings, which were boosted by a major asset sale, and the launch of its first commercial product.
2026-04-11 06:10:00
Omeros (OMER) has garnered a consensus price target from Wall Street analysts suggesting a potential upside of 266.7%. While analyst price targets can be misleading, growing optimism regarding the company's earnings prospects and a Zacks Rank #1 (Strong Buy) rating indicate a potential upside for the stock. Investors should consider these factors in conjunction, not solely relying on price targets.
2026-04-08 17:09:37
Omeros Corporation anticipates its drug YARTEMLEA will achieve financial self-sustainability by 2026. The company also projects reaching overall positive cash flow by 2027. These targets indicate a positive outlook for Omeros's financial performance in the coming years.
2026-04-05 22:40:20
Omeros Corporation has become profitable, reporting an $86.5 million net profit in Q4 2025, largely due to a $240 million asset sale to Novo Nordisk. The company also significantly reduced its debt by 47% to $88 million and successfully launched its new drug YARTEMLEA. Future revenues are anticipated from additional milestones with Novo Nordisk and an upcoming EMA regulatory decision for YARTEMLEA.
2026-04-01 16:39:17
Omeros (NASDAQ:OMER) experienced unusually high options volume, with investors acquiring 7,487 call options, a 54% increase from typical volume. This activity follows a strong Q4 earnings report where the company posted a GAAP net income of $86.5M and an EPS of $3.14, significantly beating expectations and causing the stock to rise by 15.3%. Despite mixed analyst ratings, the company has a consensus price target of $40.33, and institutional investors hold a substantial portion of its stock.
